Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma

2020175 citationsJournal Articlebronze Open Access

Authors

JapicCTI-173646.

Good health and well-being

Published in: Neuro-Oncology

Volume 23, Issue 1, pp. 122-133

Field-Weighted Citation Impact: 9.51